Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose

The main objective of this trial is to evaluate the pharmacokinetics of two evolocumab drug products in healthy participants.

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

This trial has completed. Results may be available via ClinicalTrials.gov or peer-reviewed publications.

Amgen Inc (AMGN) is the sponsoring company for this trial. BiotechSign currently grades this company C (52/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.